IQVIA Holdings Inc. (IQV) announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (DGX), for $760 million, resulting in 100 percent ownership by IQVIA.
Q2 Solutions is a global clinical laboratory services organization that provides testing, project management, supply chain, biorepository and biospecimen and consent tracking solutions for clinical trials. IQVIA previously owned a 60 percent majority share and Quest Diagnostics owned a 40 percent minority share. Quest will remain the strategic preferred laboratory provider for Q2 Solutions clients under a multi-year agreement.
IQVIA expects the deal to be approximately $0.12 accretive to 2021 adjusted EPS and at least $0.18 accretive to 2022 adjusted EPS. The company increased its full-year 2021 adjusted EPS guidance. Adjusted EPS is now expected in a range of $7.89 - $8.20, revised from prior guidance range of $7.77 - $8.08.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.